RxDoctor Payments Data

Bradley Townsend, MD

Family Medicine · Clinton, MONPI 1033205521

Payments from drug & device makers

$1,154in general payments, 2019–2025

Across 18 payments — averaging $64.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$880
  • AstraZeneca$113
  • Nevro Corp.$57
  • Lilly USA, LLC$44
  • Novo Nordisk$34
  • Pfizer$13
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$1,154100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,154 in reported general payments places this provider in the 65th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$56,428
Medicare patients
35
Services billed
604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide63$70,226
OzempicSemaglutide34$37,843
XareltoRivaroxaban19$21,747
Fiasp FlextouchInsulin Aspart (Niacinamide)11$18,913
MyrbetriqMirabegron21$12,176
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen181$6,546
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl38$6,234
Breo ElliptaFluticasone/Vilanterol12$4,906
Oxycodone Hcl89$1,356
Buprenorphine13$1,031
Fluoxetine Hcl13$729
Pregabalin23$722
Atorvastatin Calcium122$722
Albuterol Sulfate HfaAlbuterol Sulfate18$703
Diclofenac Sodium25$651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$44$70,22663 claims
Novo NordiskOzempic$34$37,84334 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Clinton

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →